Table 1.
Demographic and clinical profile of subjects.
Table 2.
aPL activity and percentage of positivity in APS, SLE and HC groups.
Fig 1.
aPL titres in APS, SLE and healthy control (HC) subjects.
Sera collected from a total of 111 patients with APS, 119 with SLE (but not APS) and 200 healthy controls were tested in nine aPL assays. Box and whisker plots running from top to bottom depict IgG, IgM and IgA titres of (running from left to right) aCL, aβ2GPI and aDI for each subject studied. The black line across data sets denotes mean activity (mean values are listed in Table 1). Abbreviations: GPLU, MPLU, APLU: IgG/IgM/IgA phospholipid units respectively; GBU, MBU, ABU: IgG/IgM/IgA β2GPI units respectively; GDIU, MDIU, ADIU: IgG/IgM/IgA DI units respectively.
Table 3.
ROC analysis: discriminatory ability of each aPL test for APS.
Fig 2.
ROC analysis: aβ2GPI tests best discriminate for APS.
Receiver operating characteristic (ROC) analysis was performed to assess the ability of each of the nine aPL assays to discriminate between APS and non-APS subjects. For all three antibody isotypes, the resulting ROC curves illustrate the superiority of aβ2GPI tests compared to aCL and aDI for APS diagnosis (numerical results are listed in Table 3). Abbreviations: GPLU, MPLU, APLU: IgG/IgM/IgA phospholipid units respectively; GBU, MBU, ABU: IgG/IgM/IgA β2GPI units respectively; GDIU, MDIU, ADIU: IgG/IgM/IgA DI units respectively.
Table 4.
Regression analysis: hazard ratio for APS.
Table 5.
Triple, double & single positivity per antibody isotype in APS.
Table 6.
Comparison of hazard ratios for APS, thrombosis and pregnancy morbidity in aCL and/or aβ2GPI positive subjects in the absence or presence of aDI.